Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
Veru (VERU) delivered earnings and revenue surprises of 14.29% and 86.99%, respectively, for the quarter ended September 2024. Do the…
0,449€
-0,20%
Echtzeit-Aktienkurs Veru
Bid:
Ask:
Nachrichten zur Veru Aktie
Veru Aktie: Erneute Rückschläge!
Die Veru Inc. verzeichnete am 30. November einen signifikanten Kursrückgang von 5,63 Prozent auf 0,67 EUR. Das biopharmazeutische Unternehmen, das…
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company…
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company…
Veru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company…
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company…
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company…
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
…
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company…